Skip to Content

Health

Central Oregon patients gain access to newly approved breakthrough cancer medication

CENTRAL OREGON (KTVZ) — The Food and Drug Administration approved daraxonrasib Aug. 26, offering a new treatment option for patients with stage 4 metastatic pancreatic cancer. Early research shows the medication doubles average life expectancy for patients with advanced stages of the disease from six to 13 months. Seven patients at St. Charles Cancer Institute

Continue Reading